Syncom Formulations (India) Limited — Board Meeting, 08-08-2025: Outcome of Board Meeting

Syncom Formulations' Board has approved the financial results for the quarter ended June 30, 2025. The company reported a consolidated revenue from operations of ₹116.90 Cr, a significant jump from ₹87.26 Cr in the same quarter last year. Consolidated profit for the period surged to ₹15.75 Cr, up from ₹7.63 Cr year-on-year. Basic and Diluted EPS for continuing operations stood at ₹0.21. The Pharmaceuticals Drugs & Formulations segment remains the key revenue driver.